A first-in-human dose escalation trial evaluated GT103, a complement factor H targeting antibody, in patients with refractory non-small cell lung cancer (NSCLC). The study, conducted across three major cancer centers, assessed safety and efficacy across multiple dose levels, marking a significant step forward in exploring complement-targeted therapy for advanced lung cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.